ICIs prevent solid and hematological malignancies from evading the natural antitumor response by targeting programmed cell death protein-1 (PD-1) receptor/ligand on T cells and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) [1]. This evidence concerns the gene CTLA4 and hematologic disorder.